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Abstract	
The	 2013‐5	 Ebolavirus	 disease	 (EVD)	 humanitarian	 crisis	 has	 spurred	 the	
development	 of	 laboratory‐free,	 point	 of	 care	 (POC)	nucleic	 acid	 testing	 (NAT)	
solutions.	EbolaCheck	is	an	 international	consortium	of	public	health,	academic	
and	 biotechnology	 industry	 stakeholders	 aiming	 to	 deliver	 clinical	 molecular	
diagnostic	 (MDx)	 standard	 of	 care	 (SOC)	 testing	 suitable	 for	 the	West	 African	
milieu	 within	 12	 months.	 In	 this	 article	 the	 current	 status	 of	 the	 EbolaCheck	
platform	is	discussed	in	the	context	of	the	current	regulatory	framework.	Future	
goals	 to	 achieve	 differential	 diagnosis	 of	 hemorrhagic	 fever	 disease	 from	 <5	
microliters	of	whole	blood	samples	(WBS)	or	mucosal	biofluids,	in	a	single	tube	
process,	in	under	40	minutes	and	with	minimal	operator	training	are	presented.	
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Background:	Clinical	diagnosis	of	Ebolavirus	disease		
Ebolavirus	 disease	 (EVD)	 is	 a	 haemorrhagic	 fever	 disease	 (HFD)	 caused	 by	
members	 of	 the	 filoviridae	 family	 of	 RNA	 viruses.	 The	 filamentous	 Ebolavirus	
virion	 (~90	 x	 1000	 nm)	 houses	 a	 7	 gene,	 ~19	 kb	 genome	 packed	 in	 a	
nucleoprotein	 (NP)	 sheath.	 Transmission	 is	 mediated	 via	 the	 Ebolavirus	
transmembrane	 glycoprotein	 (GP)	 primarily	 via	 macrophage/monocytes.	 The	
glycoprotein	also	features	immunomodulation,	immune	evasion	and	endothelial	
barrier	 disruption	 roles.[1]	 The	 monocytic	 tropism	 of	 Ebolavirus	 mediates	
proinflammatory	 responses	 during	 replication	 that	 amplify	 infectivity	 and	
pathology,	 collectively	 resulting	 in	 the	 internal	 haemorrhage	 and	organ	 failure	
characteristic	of	the	later	stages	of	disease.	[2,3]	
Diagnosis	 is	 extremely	 difficult	 [2,4]	 as	 symptoms	 mimic	 other	 HFDs,	 flu,	 or	
gastrointestinal	 infections,	which	do	not	preclude	Ebolavirus	co‐infection.	 [4,5]	
Transmission	 risk	 increases	 in	 line	 with	 symptom	 severity,	 mirroring	
viraemia;[6]	 pre‐symptomatic	 patients	 are	 not	 considered	 contagious	 and	may	
remain	 asymptomatic	 for	 up	 to	 21	 days.	 [3]	 Confirmation	 of	 Ebolavirus	 as	 the	
causal	 disease	 agent	 requires	 clinical	 molecular	 diagnostic	 (MDx)	 laboratory	
solutions.	To	date,	USD$100,	<8	hr	long,	transcription	polymerase	chain	reaction	
(RT‐PCR)	nucleic	acid	 tests	 (NAT)	on	RNA	extracts	 from	3.5	ml	of	whole	blood	
sample	(WBS)	are	the	method	of	choice.	[7]		
However,	 at	 the	 height	 of	 the	 EVD	 outbreak	 lack	 of	 capacity	 in	 West	 Africa	
required	 sample	 shipment	overseas	 resulting	 in	3‐5	day	 turnaround	 times	and	
post‐mortem	diagnosis.	 [1,8]	The	need	for	a	true	point‐of‐need	NAT	was	acute,	
yet	 no	 in	 vitro	 diagnostic	 (IVD)	 test	 had	 received	 regulatory	 clearance.	
‘Homebrew’	assays	were	based	on	Trombley	et	al.	(the	‘Trombley’	assays;	United	
States	Army	Medical	Research	Institute	for	Infectious	Disease;	USAMRIID)	[9]	or	
Panning	 et	 al..	 [10]	 These	 eventually	 received	 USFDA	 emergency	 use	
authorisation	(EUA;	EZ1	assay)	or	were	made	commercially	available	under	the	
self‐certification	CE	marking	principles	(Altona	RealStar®	Filovirus	Screen),	[11]	
respectively.	
	
Molecular	diagnostics	for	infectious	diseases	at	the	point	of	need	
Following	 9/11	 and	 the	 subsequent	 airborne	 viral	 disease	 pandemics,	 efforts	
were	 made	 to	 develop	 decentralised,	 point	 of	 care	 (POC)	 NAT’s	 [12].	 The	
resulting	solutions,	however,	were	not	designed	with	resource‐limited	settings	in	
mind,	 [13]	despite	 the	ASSURED	criteria	 espoused	by	 the	WHO.	 [14]	Thus,	 the	
need	 for	 a	 safe,	 cheap,	 simple,	 robust,	 portable	 and	 battery	 operated	 solution	
remained,	presenting	an	attractive	development	opportunity	 for	emerging	NAT	
technologies.	However,	 clinical	 development	 costs,	 [13]	 convoluted	 intellectual	
property	landscapes	and	industry	doubts	over	outbreak	duration	and	return	on	
investment	 potential,	 presented	 substantial	 obstacles.	 Poignantly,	 despite	
corporate	social	responsibility	opportunities,	to	date,	all	of	the	major	diagnostics	
manufacturers	that	engaged	in	the	Ebola	response	offered	primer‐probe	kits	for	
existing	 lab‐based	platforms,	or	developed	 ‘cassette’	kits	 for	existing,	 closer‐to‐
patient	systems.	Importantly,	these	cassette	systems	maintain	for‐profit	pricing	
structures	 for	 low	 and	 middle‐income	 countries,	 even	 following	 receipt	 of	
philanthropic	 donations	 in	 support	 of	 their	 development.	 The	
monetisation/investment	 barrier	 remains	 cornerstone	 to	 both	 regulator	 and	
non‐government	support	organisation	efforts.	[15]	
Yet	 despite	 large	 industry	 indifference	 several	 academic	 groups	 and	 start	
up/spinout	 companies	 sought	 to	 address	 the	 POC	 clinical	 diagnostic	 need.	
However,	 they	 faced	 scepticism	 from	 some	 regulatory	 bodies	 regarding	
manufacturing	 capacity,	 quality	 assurance,	 commercial	 launch/support	 and	
distribution	capability.	[16]	Thus,	little	consideration	was	given	to	post	proof‐of‐
principle,	 non‐profit	 production	 and	 distribution	 opportunities	 similar	 to	
regulator‐certified,	generic	pharmaceuticals	supply	chain	models.	Under	normal	
circumstances	 this	 would	 appear	 appropriate	 considering	 the	 high	 risk	 to	
individual	 and	 public	 health	 on	 account	 of	 false	 positive	 or	 false	 negative	
misdiagnosis	 (WHO	 category	 4	 IVD	 classification).	 However,	 on	 August	 2014	
WHO	declared	the	West	African	Ebola	outbreak	as	a	public	health	emergency	of	
international	 concern	 (PHEIC).	 Interestingly,	 this	motivated	 the	 FDA	 to	 enable	
EUA	 approvals;	 in	 contrast,	 the	WHO	 demanded	 engagement	 through	 the	 full	
pre‐qualification	 process.	 This	 diverged	 significantly	 from	 the	 documented	
successes	 with	 other	 WHO‐listed,	 FIND	 Diagnostics‐vetted,	 but	 academic‐lead	
efforts	to	address	neglected	disease	diagnostics	need.	The	net	result	was	limited	
performance	 validation	 facilitation	 (access	 to	 stored	 patient	 samples	managed	
by	 the	WHO)	 for	 innovations	 aiming	 to	 address	 the	 humanitarian	 need	 in	 the	
affected	 countries	 at	 the	 point	 of	 care,	 in	 lieu	 for	 questionable	 support	 to	
preferred	lab‐based	platforms.	
	
EbolaCheck:	the	team	
The	EbolaCheck	consortium	was	formed	in	response	to	the	August	2014	call	of	
the	Research	for	Health	in	Humanitarian	Crises	(r2hc)	programme,	managed	by	
Enhancing	 Learning	 and	 Research	 for	 Humanitarian	 Assistance	 (ELRHA;	
www.elrha.org).	 The	 Research	 for	 Health	 in	 Humanitarian	 Crises	 (R2HC)	
programme	 aims	 to	 improve	 health	 outcomes	 by	 strengthening	 the	 evidence	
base	 for	 public	 health	 interventions	 in	 humanitarian	 crises	 (visit	
www.elrha.org/work/r2hc	 for	 more	 information).	 The	 goal	 of	 the	 joint	 effort	
between	University	of	Westminster,	BioGene	Ltd.,	Public	Health	England	(PHE),	
USAMRIID,	 and	 the	 Kwame	 Nkrumah	 University	 of	 Science	 and	 Technology	
(KNUST)	funded	through	R2HC	is	to	deliver	by	November	2015	a	novel	point	of	
need	NAT	solution	for	simple,	rapid	and	safe	patient	triage	for	EVD	anywhere	in	
West	Africa.		
	
EbolaCheck:	Key	principles	
EbolaCheck	can	be	divided	into	four	sub‐systems:	the	NAT	instrument,	the	EVD	
assay,	 the	 WBS	 reaction	 formulation	 and	 the	 reaction	 consumable.	 Together,	
they	aim	to	replace	the	clinical	MDx	standard	of	care	(SOC)	with	a	rapid,	point‐
of‐need,	sample‐to‐answer	format.			
	
Low	cost	suitable	for	West	Africa	
A	 simple,	 patent‐protected,	 energy	 and	 engineering‐efficient	 method	 enables	
rapid	(<2	min),	single‐tube	access	to	pathogen	&	host	nucleic	acids	 in	biofluids	
with	 no	 need	 for	 microfluidics.	 Direct	 compatibility	 with	 standard,	
cryoprotectable	 RT‐PCR	 biochemistries	 further	 reduces	 overall	 cost.	 Crucially,	
EbolaCheck	 will	 be	 available	 to	 support	 the	 on‐going,	 WHO‐declared,	 EVD	
humanitarian	crisis	in	Africa	at	cost	only.	
	
Clinical	standard	of	care	reliability	
The	Trombley	assay	 sets	 for	Ebolavirus	Zaire	GP	and	NP	 [9]	were	migrated	 to	
EbolaCheck	 (Trombley+)	 to	 i)	 minimise	 delays,	 ii)	 avoid	 complex	 licensing	
negotiations	and	iii)	on	account	of	emerging	field	performance	evaluation	data.	
Multiplexed	use	of	 the	Trombley+	assay	sets	also	discriminate	vaccinated	 from	
infected	patients;	NP	is	not	found	in	the	two	most	advanced	EVD	clinical	vaccine	
candidates	[17,18],	a	problem	in	on‐going	vaccination	clinical	 trials	pursued	by	
other	r2hc	funded	programmes	(Gilbert	S.,	personal	communication).	USAMRIID	
have	demonstrated	performance	across	5	logs	of	viral	RNA	genome	equivalents	
(GE)	with	100%	analytical	specificity	against	65	other	pathogens	and	analytical	
sensitivities	 of	 0.001	 (NP)	 and	 0.0001	 (GP)	 plaque‐forming	 units	 (PFU)	 per	
reaction.	 [9]	The	 roughly	4,000	GE/PFU	ratio	observed	under	biosafety	 level	4	
(BSL4)	 experimentation	 [19],	 suggests	 a	 lower	 limit	 of	 detection	 (LLOD)	 of	 10	
GE/reaction,	or	104	GE/ml	of	WBS.	Given	typical	time‐to‐presentation	in	autumn	
2014	was	>3	days	post	symptom	onset,	a	LLOD	goal	of	104	GE/ml	WBS	was	set	
for	the	Trombley+	assays	on	EbolaCheck.	Present	performance	data	on	surrogate	
pseudoviral	templates	indicate	9	logs	of	quantitative	linear	dynamic	range	with	a	
lower	limit	of	quantification	of	66	GE/reaction	and	LLOD	of	6	GE/reaction,	i.e.	in	
line	with	our	performance	targets.		
	
Simple,	sample‐to‐result	standard	operating	procedure.	
The	 plethora	 of	 reports	 on	 ‘simple’	medical	 device	misuse	 by	 end‐users	 in	 the	
developed	 world	 underscore	 the	 importance	 of	 ensuring	 device	 reliability,	
particularly	with	 category	 4	 IVD	 devices	 operated	 under	 significant	 duress,	 in	
environmentally	 challenging	 conditions.	 [13]	 The	 EbolaCheck	 standard	
operating	procedure	(SOP)	consists	of:		
1)	reagent	unpacking	and	automated	rehydration,		
2)	 5	 microliter	 WBS	 collection	 by	 fingertip	 lancet	 puncture	 and	 MicroSafe®	
capillary	collection,		
3)	Sample	ejection	into	the	rehydrated	consumable,		
4)	lock	and	loading	onto	the	EbolaCheck	instrument,	and		
5)	run	initiation	by	touchscreen	input.		
Availability	 and	 status	 of	 the	 8	 random‐access	 testing	 stations	 is	 visually	
identified	 on	 the	 front‐facing	 touchscreen.	 Patient	 status	 is	 simply	 reported	 as	
positive,	negative	or	problematic,	with	the	latter	indicating	a	need	to	repeat	the	
test	due	to	a	failure.	Full	run	kinetics,	analytics	and	diagnostics	can	be	accessed	
on‐screen	or	over	a	WiFi	connection.	
		
Safety	
The	 5	 microliter	 WBS	 requirement	 of	 EbolaCheck	 presents	 a	 significant	 risk	
reduction	to	both	HCW	and	HFD	patients	compared	to	the	closed	system,	3.5	ml	
Vacutainer®	 EclipseTM	 needle	 and	 Vacutainer®	 sample	 SOC	 protocol.	 Thermal	
cycling	 is	 expected	 to	 destroy	 EVD	 [20];	 used,	 sealed	 consumables	 are	
nonetheless	discarded	as	BSL4	clinical	waste.	The	instrument	is	fully	compatible	
with	 chlorine	dioxide	 surface	 sterilisation	 [20]	 and	designed	against	 ingress	of	
liquids	 or	 internal	 condensation	 [13].	 Secure	 WiFi	 interface	 permits	 remote	
system	 checks,	 maintenance	 and	 full	 reaction	 data	 off‐boarding.	 The	 random	
access	stations	also	self‐diagnose	errors	and	automatically	shut	down	to	prevent	
misdiagnosis.	
	
Speed	
Tests	with	full	personal	protective	equipment	suggest	the	EbolaCheck	HCW	SOP	
takes	under	2	minutes	to	complete	by	minimally	trained	individuals,	with	time	to	
results	in	<40	minutes;	real	time	reaction	progression	monitoring	suggests	high	
viraemia	positive	results	could	be	called	in	as	little	as	20	minutes.		
	
Portability	
Field	 experience	 from	 in‐country	 PHE	 response	 teams	 advised	 against	 easily	
removed,	 small‐form	designs,	highlighting	 the	need	 for	higher	 throughput.	The	
ruggedized,	 8‐well	 form	maintains	 power	 supply	 independence	 through	 either	
mains	 and/or	 car	 battery/alternator	 power	 sources.	 Furthermore,	 energy	
consumption	modelling	indicates	solar	power	supply	to	be	achievable.	Design	for	
safety	 also	 achieves	 durability	 and	 reliable	 operation	 in	 savannah,	 coastal	 and	
jungle	 conditions,	 without	 corrosion	 or	 performance	 deterioration:	 simulated	
environment	tests	indicate	the	instrument	can	complete	runs	at	temperatures	as	
high	as	50oC	with	98%	humidity,	and	as	low	as	‐20oC.		
	
Development	timeline	
Prototype	design,	engineering	and	assay	development	was	initiated	in	November	
2014.	 Internal	 assay	 standards	 containing	 the	 Trombley	 assay	 targets	 were	
developed	 in	 MS2	 phage	 icosahedron	 (Armored	 RNA®)	 [21]	 (commercially	
available)	 and	 lipid	 bilayer	 enveloped	 HIV	 pseudovirus	 [22]	 (open	 access)	
formats.	 Although	 26nm	 and	 80‐100nm	 in	 size	 respectively,	 these	 represent	 a	
vast	cadre	of	viral	pathogens.	Thus,	BSL4	study	requirements	have	been	reduced	
to	 confirmatory	 studies	 using	 live	 Ebolavirus,	 and	 yielded	 data	 supporting	
EbolaCheck	platform	utility	against	other	viral	pathogens.	BSL4	studies	are	thus	
limited	to	performance	evaluation	testing	against	the	clinical	SOC	NAT	Trombley	
assay	 on	 culture	 preparations	 of	 Ebolavirus	 and	 fresh	WBS	derived	 from	non‐
human	primate	models	of	Ebolavirus	 infection.	 In‐country	testing	with	fresh	or	
stored	patient	samples	is	not	expected	on	account	of	continued	outbreak	decline	
and	 current	 WHO	 priorities	 to	 established	 technologies.	 However,	 at	 least	 3	
instruments	 will	 be	 tested	 in	West	 Africa	 using	 mock	 sample	 preparations	 to	
confirm	system	operation,	portability	and	reliability	in	urban,	rural	and	remote	
environments.	
	
Future	directions	
Our	early	data	support	multiplexed	detection	and	quantification	potential	of	3‐4	
NAT	 targets	 in	 WBS	 on	 EbolaCheck.	 As	 positive	 [23]	 and	 detrimental	 [5]	 co‐
infections	 are	 common	 amongst	 EVD	 patients,	 expansion	 of	 multiplexing	 is	
necessary,	 but	 unlikely	 to	 exceed	 concomitant	 amplification	 capability	 need	
beyond	5	targets.	Field	data	also	indicate	mucosal	biofluids	such	as	semen	[24],	
ocular	 fluid	 [25]	 and	 breast	milk	 [26]	might	 be	 viral	 depots	 in	 convalescence.	
Interestingly,	culturally	acceptable	alternatives	such	as	saliva	[27]	and	gingival‐
crevicular	fluid	[28],	might	also	be	of	use	for	HFD	diagnosis.	Thus,	demonstrating	
EbolaCheck	compatibility	with	these	mucosal	biofluids	will	expand	point	of	need	
monitoring	and	surveillance	capability	and	introduce	the	opportunity	for	needle‐
free	 testing.	 Early	 feasibility	 studies	 indicate	 this	may	 enable	 differential	 HFD	
diagnosis	with	minimal	cost	of	goods	increase.	
	
Concluding	remarks	
Of	 the	 9	 EVD	NATs	 that	 have	 received	 to	 date	USFDA	EUA,	 3	 involve	 complex	
cartridge/microfluidic	systems.	Only	the	90	minute	Cepheid	Xpert®	Ebola	assay	
(May	2015)	is	reasonably	priced	for	the	West	African	milieu	at	~US$20	per	test,	
despite	 charitable	 backing.	 With	 a	 comparable	 assay	 cadre	 and	 LLOD	 to	
EbolaCheck,	it	features	a	3	log,	non‐quantitative	dynamic	range	in	highly	diluted	
WBS,	requires	sample	pre‐processing,	multiple	mechanical	steps	and	a	separate	
personal	 computer	 and	 barcode	 scanner.	 Despite	 >10,000	 instruments	 placed	
worldwide	 this	 WHO‐selected	 platform	 costs	 US$17,000‐17,500	 to	 eligible	
countries.	Thus,	per‐unit	scaled	production	costs	are	comparable	to	the	current	
manufacturing	 cost	 of	 EbolaCheck	 prototypes	 and	 the	 Trombley+	 EVD	 assays.	
The	 EbolaCheck	 consortium	 has	 demonstrated	 that	 humanitarian	 crises	 can	
motivate	 efforts	 to	 the	 significant	 potential	 benefit	 of	 those	 in	 need	 as	well	 as	
leverage	 development	 opportunities	 for	 appropriately	 positioned	 technologies	
from	 socially	 responsible	 industry	with	 commercial	 interests	 in	 the	West.	 The	
EbolaCheck	consortium	is	presently	seeking	charitable	support	towards	scale‐up	
production	 and	 delivery	 of	 the	 first	 differential	 HFD	 diagnosis	 solution,	 to	 be	
provided	at	cost	for	any	future	WHO‐declared	humanitarian	crises.		
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